OxSonics Therapeutics

4:00 PM - 4:15 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness. OxSonics Therapeutics’ proprietary platform technology, SonoTran®, is being developed to enable a step-change in the therapeutic index of anti-cancer agents by increasing their dose and distribution within solid tumours without any development costs or delays associated with their reformulation. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time. The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
SonoTran
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2